MA71249A - Méthodes de traitement de maladies médiées par complément - Google Patents

Méthodes de traitement de maladies médiées par complément

Info

Publication number
MA71249A
MA71249A MA71249A MA71249A MA71249A MA 71249 A MA71249 A MA 71249A MA 71249 A MA71249 A MA 71249A MA 71249 A MA71249 A MA 71249A MA 71249 A MA71249 A MA 71249A
Authority
MA
Morocco
Prior art keywords
methods
mediated diseases
treating complement
complement
treating
Prior art date
Application number
MA71249A
Other languages
English (en)
Inventor
Rene Belder
Miguel Alonso ALONSO
Nazem ATASSI
Timothy Wing Yau CHOW
Pirouz SHAMSZAD
Michael John STOREK
Christopher Lawrence VINNARD
Erik Holger WALLSTROEM
Yu Jyu Nancy WONG
Original Assignee
Bioverativ Usa Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioverativ Usa Inc. filed Critical Bioverativ Usa Inc.
Publication of MA71249A publication Critical patent/MA71249A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA71249A 2022-06-24 2023-06-23 Méthodes de traitement de maladies médiées par complément MA71249A (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202263355296P 2022-06-24 2022-06-24
US202263370484P 2022-08-04 2022-08-04
US202263375041P 2022-09-08 2022-09-08
US202263379626P 2022-10-14 2022-10-14
PCT/US2023/069027 WO2023250507A1 (fr) 2022-06-24 2023-06-23 Méthodes de traitement de maladies médiées par complément
EP23745713.0A EP4543490A1 (fr) 2022-06-24 2023-06-23 Méthodes de traitement de maladies médiées par complément

Publications (1)

Publication Number Publication Date
MA71249A true MA71249A (fr) 2025-04-30

Family

ID=87474460

Family Applications (1)

Application Number Title Priority Date Filing Date
MA71249A MA71249A (fr) 2022-06-24 2023-06-23 Méthodes de traitement de maladies médiées par complément

Country Status (12)

Country Link
US (1) US20240025978A1 (fr)
EP (1) EP4543490A1 (fr)
JP (1) JP2025521565A (fr)
KR (1) KR20250029157A (fr)
CN (1) CN119730882A (fr)
AU (1) AU2023286689A1 (fr)
CA (1) CA3260415A1 (fr)
IL (1) IL317947A (fr)
MA (1) MA71249A (fr)
MX (1) MX2025000145A (fr)
TW (1) TW202417482A (fr)
WO (1) WO2023250507A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2914291T3 (da) 2012-11-02 2022-05-16 Bioverativ Usa Inc Anti-komplement-c1s-antistoffer og anvendelser deraf
CN110300520B (zh) 2016-10-12 2022-10-04 美国比奥维拉迪维股份有限公司 抗C1s抗体及其使用方法
WO2025255340A2 (fr) * 2024-06-05 2025-12-11 Genzyme Corporation Protéines de liaison ciblant ac1s, tfr, ou les deux, et compositions associées

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
EP0519596B1 (fr) 1991-05-17 2005-02-23 Merck & Co. Inc. Procédé pour réduire l'immunogénicité des domaines variables d'anticorps
EP0605522B1 (fr) 1991-09-23 1999-06-23 Medical Research Council Méthodes de production d'anticorps humanisés
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
CA2118508A1 (fr) 1992-04-24 1993-11-11 Elizabeth S. Ward Production par recombinaison genetique de domaines semblables aux immunoglobulines dans les cellules procaryotes
CA2115811A1 (fr) 1993-02-17 1994-08-18 Claus Krebber Methode de selection in vivo de proteines fixatrices de ligands
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
WO1998023289A1 (fr) 1996-11-27 1998-06-04 The General Hospital Corporation Modulation de la fixation de l'igg au fcrn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
US8591886B2 (en) 2007-07-12 2013-11-26 Gitr, Inc. Combination therapies employing GITR binding molecules
EP3722320A3 (fr) 2012-10-25 2020-12-30 Bioverativ USA Inc. Anticorps c1s anti-complément et leurs utilisations
EP2823841A1 (fr) 2013-07-09 2015-01-14 Sanofi-Aventis Deutschland GmbH Auto-injecteur
CA2981321A1 (fr) 2015-04-06 2016-10-13 True North Therapeutics, Inc. Anticorps anti-c1s humanises et leurs procedes d'utilisation
TW201707741A (zh) 2015-06-03 2017-03-01 賽諾菲阿凡提斯德意志有限公司 針頭護罩之抓握器、蓋子、自動注射器及製造抓握器之方法
TW201707738A (zh) 2015-06-03 2017-03-01 賽諾菲阿凡提斯德意志有限公司 注射器支架及自動注射器（二）
TW201711716A (zh) 2015-06-03 2017-04-01 賽諾菲阿凡提斯德意志有限公司 護罩鎖
TW201709941A (zh) 2015-06-03 2017-03-16 賽諾菲阿凡提斯德意志有限公司 聲響指示器（二）
TW201711713A (zh) 2015-06-03 2017-04-01 賽諾菲阿凡提斯德意志有限公司 藥物輸送裝置（五）
CN110300520B (zh) 2016-10-12 2022-10-04 美国比奥维拉迪维股份有限公司 抗C1s抗体及其使用方法
CR20190468A (es) * 2017-03-14 2019-12-17 Bioverativ Usa Inc Métodos para tratar enfermedades y trastornos mediados por completo
TWI808963B (zh) * 2017-03-22 2023-07-21 法商賽諾菲公司 使用人類化抗ｃｘｃｒ５抗體治療狼瘡
IL300376A (en) * 2020-08-06 2023-04-01 Bioverativ Usa Inc Inflammatory cytokines and fatigue in subjects with complement-mediated disease

Also Published As

Publication number Publication date
EP4543490A1 (fr) 2025-04-30
US20240025978A1 (en) 2024-01-25
JP2025521565A (ja) 2025-07-10
WO2023250507A1 (fr) 2023-12-28
CA3260415A1 (fr) 2023-12-28
IL317947A (en) 2025-02-01
MX2025000145A (es) 2025-09-02
TW202417482A (zh) 2024-05-01
AU2023286689A1 (en) 2025-02-06
KR20250029157A (ko) 2025-03-04
CN119730882A (zh) 2025-03-28

Similar Documents

Publication Publication Date Title
MA71249A (fr) Méthodes de traitement de maladies médiées par complément
EP3920923A4 (fr) Agents thérapeutiques et méthodes de traitement
EP4157338A4 (fr) Méthodes de traitement de maladies inflammatoires par blocage de la galectine-3
EP3996731A4 (fr) Peptides et méthodes de traitement de maladies
EP3826666A4 (fr) Compositions et méthodes de traitement de maladies associées à la nrp2
EP4103169A4 (fr) Méthodes de traitement de la tauopathie
EP4319751A4 (fr) Compositions thérapeutiques et méthodes de traitement de tumeurs
EP4121077A4 (fr) Compositions et méthodes de traitement de tumeurs solides et molles et de maladies prolifératives
EP4157251A4 (fr) Méthodes de traitement antipathogène
EP4352231A4 (fr) Traitement de maladies associées à angptl4
EP3737379A4 (fr) Compositions et méthodes de traitement de maladies métaboliques
EP3737363A4 (fr) Méthodes de traitement de maladies inflammatoires chroniques
EP4146201A4 (fr) Traitement de maladies prolifératives du snc
EP4514347A4 (fr) Traitement de troubles neurologiques
EP4413032A4 (fr) Traitement de troubles liés aux mastocytes
EP4171564A4 (fr) Méthodes de traitement de troubles neurodéveloppementaux
EP4326277A4 (fr) Méthodes de traitement de strictions d'sophagiennes
EP3866779A4 (fr) Traitement de maladies neurologiques
EP4099997A4 (fr) Méthodes et compositions pour le traitement de maladies
EP4117655A4 (fr) Méthodes de traitement
EP4188546A4 (fr) Traitement de maladies virales
EP4204401A4 (fr) Composés et méthodes de traitement de maladies
EP4466064A4 (fr) Traitement de troubles inflammatoires
EP4228599A4 (fr) Méthodes de traitement de la dystonie cervicale
EP3938364A4 (fr) Composés et méthodes de traitement de maladies